Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06244940 · ClinicalTrials.gov registry record · NA
The Sequencing for Detection in Congenital Heart Disease (SD-CHD) Study
A NA study of Congenital Heart Disease, sponsored by Scripps Translational Science Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT06244940: Recruiting NA study of Congenital Heart Disease, sponsored by Scripps Translational Science Institute.
NCT06244940 is a NA study of Congenital Heart Disease that is actively recruiting participants, run by Scripps Translational Science Institute. The registered enrollment target is 200 participants, below the 471-participant average among 63 other Congenital Heart Disease trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06244940, a NA study of Congenital Heart Disease, is actively recruiting participants, sponsored by Scripps Translational Science Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is enrolling pregnant persons treated at Rady Children's Hospital fetal cardiology program with a prenatal diagnosis of congenital heart disease to look for genetic disorders in the fetus or unborn baby. Congenital heart disease (CHD) is a group of structural differences to the heart that represent the most common birth defect among liveborn infants world-wide. CHD is the leading cause of birth-defect associated infant death. Prenatal detection allows for delivery planning, postnatal repair, specialized medications, and detailed counseling for parents. Up to one in three fetuses with CHD may have a genetic cause. In babies, knowing about genetic diseases helps patients and doctors provide the best care for their babies. If identified prenatally, this same knowledge may help participants prepare for their location of delivery, meet with specialists, and consider specialized treatments and medications that may be appropriate. The diagnostic yield and clinical utility of whole genome sequencing (WGS) in fetuses with prenatally detected congenital heart disease (CHD) will be compared to routine clinical testing in patients choosing amniocentesis or chorionic villus sampling. DNA will be obtained from fetal samples and biological parent blood samples and analyzed according to standard clinical interpretation guidelines. Results will be reported to healthcare providers and patients and measures of clinical utility will be collected. Additionally, measures of stress, anxiety, depression, and perceived utility of information will be assessed by validated survey tools. A historical cohort of patients electing for diagnostic procedures will be used as a comparison population.
Primary Outcome
Trios with pathogenic or likely pathogenic sequencing results/ total number of trios.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Whole Genome Sequencing (WGC) from subject samples
Study Locations (1)
California
- Rady Children's Institute for Genomic Medicine - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-01-09 |
| Est. Completion | 2026-10-01 |
| Phase | NA |
What NCT06244940 shows while recruiting
NCT06244940 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 471-participant average among 63 other Congenital Heart Disease trials with a reported enrollment target (58% lower).
The record links to 1 condition, with Congenital Heart Disease appearing as the primary indexed condition, and to 1 intervention - of which Whole Genome Sequencing (WGC) from subject samples is the first listed.
NCT06244940 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06244940 about?
NCT06244940 is a clinical study titled "The Sequencing for Detection in Congenital Heart Disease (SD-CHD) Study". This study is enrolling pregnant persons treated at Rady Children's Hospital fetal cardiology program with a prenatal diagnosis of congenital heart disease to look for genetic disorders in the fetus or unborn baby. Congenital heart disease (CHD) is a group of structural differences to the heart tha...
What is the current status of trial NCT06244940?
This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2024-01-09. Estimated completion is 2026-10-01.
What conditions does trial NCT06244940 study?
This clinical trial studies the following conditions: Congenital Heart Disease.
What interventions are being tested in trial NCT06244940?
The interventions under investigation include: Whole Genome Sequencing (WGC) from subject samples (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06244940?
This trial is sponsored by Scripps Translational Science Institute, which has 41 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06244940 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congenital Heart Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06244940's enrollment target sits among peer trials
200 17th of 63 higher than 42 of 63 other Congenital Heart Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Congenital Heart Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Fontan Fitness Trial
RECRUITING · NA
-
Blood Conservation in Patients (3.5-12kg) Undergoing Congenital Cardiac Surgery
RECRUITING · NA
-
Starlight Cardiovascular Lifeline Ductus Arteriosus Stent IDE Study
RECRUITING · NA
-
A Study of Hemodynamic Cardiopulmonary Exercise for CHD
RECRUITING · NA
-
Ventripoint Single Ventricle Study
RECRUITING · NA
-
Parent Navigator Program (PNP) to Improve Outcomes in Latino/x Children and Parents
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI